


NKF ADVISED GENFIT ON ITS ACQUISITION OF VERSANTIS

Posted on 4 October 2022



Categories: [Deal & transactions](#), [Tax](#)

Tags: [Andreas Casutt](#), [Christina Rinne](#), [Daniela Lötscher](#), [Daniela Schmucki](#), [Jamie Mancini](#), [Julia Tolstova](#), [Morgan Boëffard](#), [Niederer Kraft Frey](#), [Philipp Haas](#), [Shu Bernet-Zhang](#), [Slider](#), [Ulysses von Salis](#)



Niederer Kraft Frey has advised **GENFIT**, a late-stage biopharmaceutical company, on the acquisition of **Versantis**. GENFIT is a pioneer in liver disease research and development, publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext's regulated market in Paris. The acquired Versantis is a clinical stage biotechnology company focused on addressing the growing, unmet medical need in liver diseases.

This partnership enables the combination of Versantis' experience with GENFIT's expertise in conducting complex development programmes in liver diseases. The acquisition further strengthens GENFIT's position as a leader in acute-chronic liver failure (ACLF) and significantly expands its product portfolio.

The **NKF** team was led by corporate/m&a partner **Philipp Haas** (pictured left) and tax partner **Daniela Schmucki** (pictured right), working with senior associates **Shu Bernet-Zhang** and **Julia Tolstova** (both corporate/m&a) as well as partners **Ulysses von Salis** (corporate/m&a), **Christina Rinne** (tax) and **Andreas Casutt** (employment), senior associate **Morgan Boëffard** (tax), associate **Daniela Lötscher** (employment) and associate **Jamie Lee Mancini** (real estate).